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Abstract
Recent human clinical trials results demonstrated successful treatment for certain genetic forms of 
cystic fibrosis (CF). To extend treatment opportunities to those afflicted with other genetic forms 
of CF disease, structural and biophysical characterization of CF transmembrane conductance 
regulator (CFTR) is urgently needed. In this study, CFTR was modified with various tags, 
including a His10 purification tag, the SUMOstar (SUMO*) domain, an extracellular FLAG 
epitope, or an enhanced green fluorescent protein (EGFP), each alone or in various combinations. 
Expressed in HEK293 cells, recombinant CFTR proteins underwent complex glycosylation, 
compartmentalized with the plasma membrane, and exhibited regulated chloride-channel activity 
with only modest alterations in channel conductance and gating kinetics. Surface CFTR 
expression level was enhanced by the presence of SUMO* on the N-terminus. Quantitative mass-
spectrometric analysis indicated approximately 10% of the total recombinant CFTR (SUMO*-
CFTRFLAG-EGFP) localized to the plasma membrane. Trial purification using dodecylmaltoside 
for membrane protein extraction reproducibly recovered 178 ± 56 μg SUMO*-CFTRFLAG-EGFP 
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per billion cells at 80% purity. Fluorescence size-exclusion chromatography indicated purified 
CFTR was monodisperse. These findings demonstrate a stable mammalian cell expression system 
capable of producing human CFTR of sufficient quality and quantity to augment futrure CF drug 
discovery efforts, including biophysical and structural studies.
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INTRODUCTION
Cystic fibrosis (CF) is the most common fatal genetic disease in the western world, with an 
incidence of approximately 1 in 2500 births (1). CF is caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene that encodes a chloride channel 
belonging to the ATP-binding cassette (ABC) transporter superfamily (2, 3). Defects of 
CFTR channel function compromise epithelial transcellular fluid regulation in the lungs, 
pancreas and other organs, and lead to thickening of mucus in the lungs, and eventually 
tissue sequelae and death. Other complications of CF include malnutrition due to pancreatic 
insufficiency, electrolyte imbalances, diabetes and male infertility. The most frequent 
genetic mutation associated with clinical CF disease is deletion of phenylalanine at position 
508 (ΔF508) in CFTR. The ΔF508 mutation results in aberrant folding of the CFTR protein, 
retention of CFTR in the endoplasmic reticulum and premature CFTR protein degradation 
(4). Interestingly, wild-type CFTR (wtCFTR) appears to fold, mature, and reach the plasma 
membrane less efficiently compared to other ABC transporters (5-7). Cellular quality 
control appears to be quite stringent, and even mature CFTR at the cell-surface is 
endocytosed at a rate of ~10% per min in normal cells (8). N-glycosylation is intimately 
linked with CFTR folding in the endoplasmic reticulum, and maturation in the Golgi 
apparatus of glycan chains from the core-glycosylated form (band B) of CFTR to the final 
complex-glycosylated form (band C) often is used experimentally as a surrogate for proper 
CFTR folding and trafficking to the cell-surface (6, 9).
The architecture of CFTR is similar to that of other ABC transporters, consisting of 
transmembrane domains harboring the chloride pore, connected by cytoplasmic loops to two 
nucleotide binding domains (NBDs) that hydrolyze ATP (10, 11). CFTR features a unique 
regulatory (R) region that, when phosphorylated, regulates ATP hydrolysis-mediated 
channel gating (7, 12). Limited insights toward understanding this complex structure, 
interactions between subdomains, and preliminary functional models have been provided by 
low resolution structures of full-length CFTR, crosslinking experiments, nuclear magnetic 
resonance studies of partial molecules, and molecular modeling based on crystal structures 
of other ABC transporters (13-16).
Drug discovery efforts based on a variety of CFTR ‘correctors’ that improve trafficking of 
misfolded protein to the plasma membrane or ‘potentiators’ that improve channel function 
(17) were initially disappointing due to poor potency of the compounds (18-20). However, 
the recent FDA approval and clinical success using ivacaftor to treat CF patients with CFTR 
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pharmacogenetics/ucm290088.htm) firmly validates rationale for the discovery of small-
molecule CF drugs. Since patients with gating mutations and other mutations that can be 
treated with Ivacaftor represent fewer than 15% of the over 1900 CF-causing mutations 
identified to date (http://www.cftr2.org/), it seems likely that numerous CF drugs will be 
needed to extend treatment opportunities to greater numbers of individuals afflicted with CF 
(21). To augment drug discovery, direct structural and biophysical characterization of wild-
type and mutated forms of CFTR is urgently needed, but has been impeded by both 
difficulties producing significant quantities of CFTR and the limited stability of purified 
protein. The goal of the present study was to characterize a molecular expression strategy 
that was conceived to facilitate the identification and derivation of stable cell lines for high-
level production of full-length CFTR. Our results demonstrated robust expression in human 
embryonic kidney (HEK) epithelial cells of exogenous full-length human CFTR comprising 
various domains and tags that facilitate the derivation of stable high-producer cell lines, 
assessment of CFTR biogenesis, and characterization of recombinant CFTR protein. These 
findings are significant as they demonstrate a mammalian cell expression system capable of 




Schematics of the HIV-1-based lentiviral vectors used in these studies are shown in Fig. 1. 
The basic molecular genetic structure of these vectors included LTR-ψ-RRE-CTS/PPT-
TRE-MCS-IRES-Puro-WPRE-ΔU3.LTR (LTR, long-terminal repeat; ψ, psi/RNA genome 
packaging signal; RRE, Rev response element; CTS, central termination sequence; PPT, 
polypurine tract; TRE, tetracycline response element; MCS, multiple cloning site; IRES, 
internal ribosome entry site; Puro, puromycin N-acetyl-transferase gene; WPRE, woodchuck 
hepatitis virus post-transcriptional regulatory element; and ΔU3.LTR, deletion in the U3 
sequence of the LTR). Most of these genetic elements have been described previously 
(22-28). The arrangement of the TRE and IRES allows genes inserted into the MCS and 
those downstream of the IRES to be expressed from a single mRNA transcript.
The TRE-CFTR-IRES-Puro.T2A.EGFP vector (K2933) was derived from a wtCFTR 
expression vector described previously (29) by inserting a Puro element followed by a 
Thosea asigna 2A-like peptide (T2A) coding sequence upstream and in-frame with 
enhanced green fluorescent protein (EGFP) (30-32). The CFTR FLAG-containing 
expression vector, TRE-CFTRFLAG-IRES-Puro (K3103) was created by polymerase chain 
reaction (PCR) amplification of a CFTR sequence containing the FLAG octapeptide epitope 
(DYKDDDDK) after residue N901 (33, 34), and its ligation into the 5’ NheI and 3’ XhoI 
sites of the lentiviral vector. Published studies indicate that inclusion of a FLAG tag in the 
4th extracellular loop (proximal to residue 901) enables cell surface localization of CFTR 
without altering its expression (33, 34). The expression vector, TRE-CFTRFLAG-EGFP-
IRES-Puro (K3290), was generated by ligating an A206K mutated EGFP (25) sequence in-
frame and downstream of CFTRFLAG. The translational stop codon of CFTR was eliminated 
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and a tobacco etch virus (TEV) protease cleavage site (underlined) (35) and a glycine-serine 
hinge were introduced between the CFTRFLAG and EGFP genes (CFTRFLAG-
ENLYFQGGGGSGGSS-EGFP). The TRE-SUMO*-CFTRFLAG-EGFP-IRES-Puro 
expression vector (K3235) was generated by inserting a DNA segment coding for 
MERGSH10-LVPRGSAS-SUMOstar (synthesized by GeneArt/Life Sciences) in-frame at 
the 5’ end of CFTRFLAG-EGFP. The N-terminal RGSHis10 tag enables affinity purification 
and immunodetection of the recombinant protein. The His-tag is cleavable by the presence 
of a Thrombin protease cleavage site (underlined). Small ubiquitin-like modifier (SUMO, 
Saccharomyces cerevisiae Smt3) and SUMOstar (SUMO*) domains have been shown to 
enhance folding and solubility of fused recombinant proteins (36, 37), including isolated 
CFTR NBDs (38). SUMO* is modified at two interfacial amino acids, R64T and R71E, 
rendering resistance to cleavage by intrinsic eukaryotic proteases (39). The SUMO* 
polypeptide can be removed from its fusion partner with specific proteases (37, 40). The 
integrity of each of the recombinant expression vectors was confirmed by nucleotide 
sequence analysis. The entire ORF sequence of SUMO*-CFTRFLAG-EGFP was deposited in 
GenBank (accession KP202880).
Cell lines and growth conditions
HEK293 (293F; Invitrogen), HEK293.M2 (D017) (41), and cell lines derived from 
HEK293.M2 cells by lentiviral vector transduction were maintained as adherent cultures in 
DMEM/F12 medium supplemented to contain 10% fetal bovine serum (FBS) (HyClone), 
100 U/mL penicillin and 0.1 mg/mL streptomycin (Life Technologies). The HEK293.M2 
cell line (41) constitutively expresses a modified form of the reverse tetracycline 
transactivator (rtTA-M2) for specific and sensitive doxycycline (dox)-inducible gene 
expression under control of the tetracycline response element (42). All HEK293-derived cell 
lines that were adapted to serum-free suspension-culture, were maintained in 
CDM4HEK293 medium (HyClone) supplemented to contain 100 U/mL penicillin, 0.1 
mg/mL streptomycin, 2 mM L-glutamine, 2 mM L-alanyl-L-glutamine dipeptide, 0.25 
μg/mL amphotericin B, and 1:1000 (v:v) anti-clumping agent (Life Technologies). 
Suspension culture-adapted cells were propagated in either 1050 cm2 smooth surface roller 
bottles (Thermo Scientific) or a 14L autoclavable bioreactor supported by a New Brunswick 
BioFlo 310 benchtop fermentor system (Eppendorf) http://newbrunswick.eppendorf.com/en/
products/fermentors/.
Generation of recombinant CFTR cell lines
The 293T/17 cell line (ATCC®) used for packaging of all lentiviral vector stocks was 
maintained in DMEM supplemented to contain 10% FBS, 100 U/mL penicillin and 0.1 
mg/mL streptomycin. Lentiviral vector genomes containing the different CFTR genetic 
recombinants were packaged by cotransfecting 293T/17 cells with pCMVΔR8.2 packaging 
plasmid DNA and vesicular stomatitis virus envelope glycoprotein plasmid DNA (24, 43). 
Culture supernatants were collected after 60 hrs, clarified by low-speed centrifugation (250 
× g, 10 min), filtered through 0.45 μm sterile filters, and concentrated by ultracentrifugation 
at 125,000 × g at 4°C for 2 hrs. For transduction, 105 HEK293.M2 (D017) cells in 200 μl of 
DMEM/F12/1% FBS were incubated with concentrated packaged vector at 37°C for 18 hrs. 
After 2-3 days, 1 μg/ml dox was added to the culture medium, and 24 and 48 hrs later, 
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transgene expression was assessed by fluorescence microscopy. Cultures exhibiting a 
positive response in less than 40% of the cell population were discarded. Those with 
favorable expression were cultured for 7-9 days in the presence of 10 μg/ml puromycin. All 
selected cell cultures were confirmed to be >95% expression-positive for the respective 
transgene by monitoring either EGFP or CFTR as described below. Puromycin-selected cell 
populations were expanded in the absence of dox and puromycin and cryopreserved in liquid 
nitrogen. Subsequent studies of the different CFTR cell lines were performed with 
monolayer cultures, except where suspension-culture-adapted cells have been specified.
Western blot analysis
Western blot analysis of cells expressing recombinant CFTR was performed using methods 
reported earlier (44, 45). Briefly, cells were solubilized in sample buffer (46), sonicated, and 
heated at 37°C for 5 min prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) in 7% gels. Proteins were transferred to nitrocellulose by electroblotting, and 
detected using either anti-RGSHis4 (Qiagen) or R1104 anti-CFTR mouse monoclonal 
antibody recognizing an epitope comprising amino acids 722-734 in the CFTR regulatory 
(R) region (47). Horseradish peroxidase-conjugated goat anti-mouse IgG (Southern Biotech) 
was used as secondary antibody with Immobilon Western Chemiluminescent substrate 
(Millipore). The chemiluminescent signal was captured and analyzed on an ImageQuant 
LAS 4000 Mini luminescent image analyzer (GE Healthcare Life Sciences).
Flow cytometry
Cellular expression and plasma membrane compartmentalization of CFTR were analyzed 
using flow cytometry to detect EGFP expression and FLAG immunostaining. Live cells 
were equilibrated in room temperature (RT) staining buffer for 15 min, incubated with 5 
μg/ml of SureLight APC anti-FLAG M2 mAb for 30 min at RT, washed three times with 
ice-cold staining buffer, detached by incubation on ice with phosphate-buffered saline 
containing 0.5 mM EDTA, washed once with staining buffer and resuspended in 200 μl 
Cytofix (BD Biosciences). Both EGFP fluorescence and FLAG/CFTR staining were 
measured using a BD FACSCalibur or LSRII flow cytometer (BD Biosciences). Negative/
positive fluorescence boundaries were determined using HEK293.M2 cells. Flow cytometric 
data were analyzed using FlowJo software.
Derivation of clonal cell cultures
All recombinant CFTR cell lines analyzed in this study comprised mass populations of 
transduced cells unless otherwise noted. To generate clonal cell lines, cultures treated for 
18-24 hrs with 1 μg/ml of dox were live-stained using SureLight allophycocyanin (APC)-
conjugated anti-FLAG M2 (PerkinElmer). The most highly fluorescent cells (top 10%) were 
sorted individually into wells of 96-well plates using a FACS Aria (BD Biosciences). Initial 
screening of clonal cell cultures included analyses of cellular morphology, growth kinetics, 
and levels of basal and dox-induced EGFP and/or FLAG/CFTR expression using 
fluorescence microscopy. Clonal cultures exhibiting favorable characteristics were expanded 
for further analyses and cryopreservation of master stocks. Clonal cell lines adapted to 
serum-free suspension-culture were reanalyzed to ensure growth kinetics. Relative CFTR 
expression levels in suspension culture adapted cells were not predictable based on the 
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analysis of the corresponding monolayer cells, and therefore, CFTR expression properties 
were re-determined in each instance. To confirm the integrity of the recombinant CFTR 
sequence in the D165 clonal line, PCR amplicons comprising the SUMO*-CFTRFLAG-
EGFP open reading frame were generated by PCR, sequenced without cloning, and found to 
be identical to the transducing vector (data not shown).
Single-channel recording
Microsomal membrane fractions were prepared from the HEK293-derived cell lines 
overexpressing CFTR recombinant proteins or from BHK cells constitutively expressing 
wtCFTR, as described previously confirm citation (48). Membrane vesicles were 
phosphorylated by incubation with 50 nM PKA catalytic subunit (Promega) and 2 mM 
Na2ATP (Sigma-Aldrich) in 10 mM Hepes, pH 7.2, 0.5 mM EGTA, 2 mM MgCl2, and 250 
mM sucrose at RT for 15 min. Aliquots were stored at −80°C until used. Microsomal 
vesicles were fused to planar lipid bilayers and single-channel currents were recorded at 
30°C in symmetrical buffer (300 mM Tris HCl pH 7.2, 3 mM MgCl2, 1 mM EGTA) at −75 
mV under voltage-clamp conditions as described previously (49). To maintain uniform 
channel orientation and optimal functional state, 2 mM Na2ATP, 50 nM PKA and 10 μl 
membrane vesicles were added to the one side of the bilayer only. Output signal was filtered 
with a cut-off frequency of 50 Hz.
Fluorescence microscopy
Cells in 8-chamber glass slides (Falcon CultureSlide) coated with bovine type I collagen 
(BD Biosciences) were treated with dox for 24 hrs. Live cells were immunostained without 
fixation by incubation on ice with 5 μg/ml anti-FLAG M2 mAb (Sigma-Aldrich) followed 
by cold washing and incubation with Alexa Flur® 594-conjugated goat anti-mouse IgG (H
+L) antibody (Life Technologies) on ice for 30 min. Cells were washed with cold staining 
buffer (BD Biosciences), and then fixed for 15 min with Cytofix (BD Biosciences). Cells 
were washed, cured with ProLong® Gold antifade reagent containing 4’,6’-diamidino-2-
phenylindole (DAPI) (Life Technologies) to stain cell nuclei, and mounted with a coverslip. 
Confocal images were acquired using a Zeiss LSM 710 confocal microscope with a 63x 
PlanApo oil immersion objective at a resolution of 1024x1024 pixels. A Helium Neon 561 
nm excitation laser was used to excite Alexa Flur® 594 and image spectra at 590-700 nm. 
Optical sections in the z-axis (z-stack) were acquired at 0.45 micron intervals. Images of 
DAPI-stained cell nuclei (blue) were acquired using a 405 nm laser. For protein 
colocalization studies, fluorescence was analyzed using a Nikon Eclipse TE2000-S inverted 
microscope equipped with an Xcite 120 Fluorescent Illumination system. Images were 
captured and analyzed using a SPOT RT3 25.4 Color Slider camera (Diagnostics Imaging, 
Inc., SPOT™ Imaging Solutions division) supported with Qcapture Pro software 
(QImaging, Inc.).
Mass spectrometry quantitation of cell-surface CFTR
Heavy isotope-labeled CFTR was prepared from baby hamster kidney (BHK) cells 
expressing wtCFTR as described previously (50) using 99% atom-enriched 1,2-[13C]2-L-
leucine as the isotope-labeled amino acid. A purified CFTR external standard was used to 
Hildebrandt et al. Page 6













determine concentrations of labeled CFTR present in Triton X-100 cellular extracts prepared 
from the BHK cells (50). To specifically quantify CFTR compartmentalized in the plasma 
membrane, intact cells were surface biotinylated and biotinylated protein was isolated using 
the EZ-Link Sulfo-NHS-SS-Biotin kit (Thermo Scientific). Protein fractions (biotinylated 
protein or Triton X-100 cell extracts) were spiked with the L-leucine isotope-labeled cell 
lysate, and then subjected to SDS-PAGE, in-gel protein digestion and peptide cleanup as 
previously described previously (50). Three human CFTR signature peptides designated 
CFTR01, CFTR02 and CFTR04 of the sequences shown in Table 1 were used to quantify 
the isolated CFTR protein fractions using liquid chromatography multiple reaction 
monitoring-mass spectrometry (50, 51). The instruments used were an Eksigent NanoLC-
ultra 2D Plus liquid chromatograph and 4000 QTrap mass spectrometer (ABSCIEX).
CFTR purification
SUMO*-CFTRFLAG-EGFP was solubilized from microsomal membranes with n-dodecyl-β-
D-maltoside (DDM) and affinity purified using NiNTA resin (Qiagen) according to 
manufacturer-recommended procedures. In-gel fluorescence with external standards was 
used to quantify SUMO*-CFTRFLAG-EGFP in crude and purified fractions (52). Samples 
were resolved on 8% SDS-PAGE gels together with known amounts of SUMO-EGFP 
fusion protein (39 kD, LifeSensors). Fluorescence of EGFP-tagged proteins was imaged 
using a Typhoon scanner (GE Healthcare), and densitometry of fluorescent bands was 
performed in ImageJ (http://imagej.nih.gov/ij/).
Fluorescence size exclusion chromatography (FSEC)
FSEC of purified SUMO*-CFTRFLAG-EGFP was performed on a 3.2 mm × 30 cm Superose 
6 column (GE Healthcare) in 50 mM Tris Cl pH 7.5, 0.15 M NaCl, 10% glycerol, 2.5 mM 
MgCl2, 0.05% DDM, 0.2 mM tris(2-carboxyethyl)phosphine, flowing at 0.04 ml/min. EGFP 
fluorescence was monitored at 488 nm/509 nm using a Jasco FP2020 Plus fluorimetric 
detector, with gain set at 100 and attenuation at 64.
RESULTS
Analysis of recombinant CFTR protein expression
To explore the utility and performance of various in-frame domain fusions of recombinant 
CFTR, the HEK293.M2 cell line (41) was transduced with either the SUMO*-CFTRFLAG-
EGFP, SUMO*-CFTR-EGFP, CFTRFLAG-EGFP, CFTRFLAG, or wtCFTR expression 
vector (Fig. 1). The resulting cultures were induced with dox for 24 hrs and CFTR 
expression was analyzed by Western blot (Fig. 2). Replicate blots were probed with either 
anti-CFTR mAb (R1104) or N-terminal-specific anti-RGSHis4 mAb. SUMO*-CFTRFLAG-
EGFP, CFTRFLAG and CFTR proteins were detected at similar levels, and slightly higher 
than CFTRFLAG-EGFP (lane 4). SUMO*-CFTRFLAG-EGFP (lane 1) resolved into a double 
band, indicating expression of both core-glycosylated (band B) and complex glycosylated 
(band C) CFTR. Greater electrophoretic mobility of CFTRFLAG compared to CFTR was 
evident on SDS-gels (lane 6 vs 5, also lane 1 vs 2), and is likely due to disruption of one of 
the two glycosylation sites caused by insertion of the FLAG epitope (33, 34, 53, 54). The 
CFTRFLAG-EGFP protein exhibited both bands B and C (lane 4), while wtCFTR and 
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CFTRFLAG (lanes 5 and 6, respectively) were expressed at high levels with a predominance 
of band C. Cells expressing the ΔF508 form of SUMO*-CFTRFLAG-EGFP (lane 3) 
exhibited reduced expression of band C, consistent with expectations for this CFTR mutant 
to be retained in the endoplasmic reticulum (ER) in its core-glycosylated form (4, 55). D165 
(lane 7) is a clonal derivative of the SUMO*-CFTRFLAG-EGFP cell population (lane 1), 
which exhibited a similar immunoblot phenotype. These results provided qualitative 
evidence that the cell expression system utilized can produce recombinant CFTR containing 
various tags, including the multiply tagged SUMO*-CFTRFLAG-EGFP recombinant protein.
Cells expressing CFTRFLAG, CFTRFLAG-EGFP, SUMO*-CFTRFLAG-EGFP (D158) and its 
clonal derivative (D165), were analyzed using flow cytometric methods to compare CFTR 
expression levels and surface compartmentalization. Cells transduced with CFTRFLAG 
stained positive for the FLAG epitope, and each of the CFTRFLAG–EGFP-containing cell 
lines was decidedly positive for both EGFP and FLAG staining (Fig. 3A). Importantly, since 
immunostaining was performed on live/intact cells, positive FLAG staining indicated 
compartmentalization of the recombinant CFTR protein in the plasma membrane (and see 
Fig. 5). The overall magnitude of EGFP and FLAG-stain fluorescence was reproducibly 
greater for SUMO*-CFTRFLAG-EGFP (both D158 and D165 cell lines) compared to 
CFTRFLAG-EGFP, possibly due to enhanced stability. Similarly, cell-surface FLAG staining 
of CFTRFLAG appeared to be greater than that of CFTRFLAG-EGFP. The flow cytometric 
distribution of the clonal (D165) SUMO*-CFTRFLAG-EGFP cell population was similar to 
the nonclonal (D158) population, but with a greater proportion of dual-positive cells. To 
quantitatively compare surface expression of the SUMO*-CFTRFLAG-EGFP and 
CFTRFLAG-EGFP recombinant proteins, the respective cell lines were induced with dox for 
24, 48 and 72 hrs, live-stained for FLAG, and analyzed by flow cytometry (Fig. 3B). Mean 
fluorescence intensity (MFI) values for SUMO*-CFTRFLAG-EGFP were greater at each 
time point compared to CFTRFLAG-EGFP, with the greatest difference observed 24 hrs after 
induction. These differences in surface CFTR expression level were consistent with the 
degree of complex glycosylation observed by Western blot analysis (Fig. 2). These results 
suggest that introducing the N-terminally fused SUMO* domain to CFTRFLAGEGFP 
increased its cell-surface expression of the protein.
Channel activity of CFTR in cell membranes
Single channel recording provides a means to validate function of recombinant CFTR 
function (56, 57). Expressed wtCFTR in BHK and HEK cell lines (Fig. 4) exhibited single-
channel conductance (γ) of 12.3 ± 0.1 pS (n=6) and 12.2 ± 0.1 pS (n=7), respectively. Slight 
differences in conductance and gating kinetics were not significant, indicating the channel 
properties of untagged wtCFTR were independent of the cell line in which it was expressed. 
Modification of CFTR with both SUMO* and EGFP tags (Fig. 4) did not affect single 
channel conductance, but approximately doubled the mean closed time (τc) with no 
significant change in the mean open time (τo). As a result, the open probability (Po) 
decreased approximately two-fold, to 0.26. CFTRFLAG exhibited a single-channel 
conductance of 11.5 ± 0.1 pS (n=7), which was a statistically significant reduction compared 
to wt CFTR (P<0.05), and could reflect the influence of additional negative charge (due to 
FLAG sequence, DYKDDDDK) near the outer vestibule. Po and gating kinetics of 
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CFTRFLAG were essentially the same as those of the SUMO*-CFTR-EGFP construct. The 
CFTR construct containing all three tags, SUMO*-CFTRFLAG-EGFP, had the same 
conductance as CFTRFLAG and gating kinetics typical of the individually SUMO*- or 
FLAG-tagged constructs. The influence of the latter two modifications on gating kinetics 
was not additive.
Microscopic visualization of CFTR surface localization
Expression of recombinant SUMO*-CFTRFLAG-EGFP protein was initially analyzed by 
immunofluorescence confocal microscopy. Dox-induced cells, live-stained to specifically 
detect surface FLAG, exhibited a strong fluorescence pattern particularly evident along the 
cell periphery. A z-stack of acquired images illustrates a strong punctate pattern of FLAG 
staining (red) that is broadly distributed across the cells (Fig. 5A). The control non-FLAG-
stained cells exhibited no Alexa Flur® fluorescence (data not shown). In fluorescence 
microscopy colocalization experiments, FLAG immunostaining (red) was detected with 
live-stained cells expressing SUMO*-CFTRFLAG-EGFP (Fig. 5B), but not (FLAG-less) 
SUMO*-CFTR-EGFP cells (Fig. 5C). In each cell type, EGFP was detected throughout the 
cell (green), with the brightest areas of fluorescence appearing along portions of the cell 
periphery and at cell-cell interfaces. Merging the FLAG and EGFP fluorescent images 
demonstrated extensive colocalization of the two domains at the plasma membrane. FLAG 
immunostaining of fixed, permeabilized cells expressing SUMO*-CFTRFLAG-EGFP (Fig. 
5D) demonstrated a subcellular localization pattern similar to that of EGFP, further 
establishing colocalization of EGFP with CFTR protein. These results indicate 
compartmentalization at the plasma membrane of the recombinant SUMO*-CFTRFLAG-
EGFP protein.
Quantitative analysis of CFTR expression by mass spectrometry
Since the rtTA-M2 enables incremental control of transcription, SUMO*-CFTRFLAG-EGFP 
expression was induced by treating cells with different concentrations of dox, ranging from 
0.0007 to 0.5 μg/ml. Cells were collected after 24 hrs and analyzed for surface CFTR. Flow 
cytometric analysis demonstrated a dose-response effect of dox concentration on surface 
FLAG/CFTR expression level (Fig. 6A). Samples from the same cultures were further 
analyzed by surface biotinylation and mass spectrometry to quantify surface CFTR. In this 
experiment, cell-surface CFTR levels plateaued at ~400 μg per 109 cells, or 1.1 × 106 
molecules CFTR per cell (Fig. 6B). In three independent experiments, the average 
maximum induced level of surface CFTR was 363 ± 31 μg per 109 cells. The average level 
of total cellular CFTR was 3581 ± μg per 109 cells (Table 2). Thus, when overexpressed at 
these high levels, ~1/10th of the CFTR synthesized was present on the cell-surface. Over the 
range of dox concentrations analyzed there was a very strong linear correlation (r2 = 0.961) 
between mass spectrometric and flow cytometric measurements of cell-surface SUMO*-
CFTRFLAG-EGFP (Fig. 6C). These results indicated that HEK293.M2 cells biosynthesize 
and traffic appreciable quantities of recombinant CFTR to the plasma membrane, and flow 
cytometry of cells live-stained for the FLAG epitope can be used to assess CFTR surface 
expression.
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Demonstration of CFTR purification using a mild detergent
Inclusion of EGFP in the recombinant SUMO*-CFTRFLAG-EGFP protein makes it possible 
to quantify CFTR even in crude cell lysates using in-gel fluorescence (52). We applied this 
method to quantify SUMO*-CFTR-EGFP in microsomal membranes, and monitor its 
recovery through the trial protein purification shown in Fig. 7. The starting material, a 
microsomal fraction of 0.15x109 cells harvested from a 1 liter serum-free suspension-
culture, contained 235 μg of SUMO*-CFTRFLAG-EGFP (1600 μg per 109 cells). DDM is a 
preferred mild detergent for structural biology, but it has been successfully applied for 
CFTR purification only with low-expressing mammalian cell lines (57, 58). Extraction of 
microsomes with DDM solubilized 221 μg of SUMO*-CFTRFLAG-EGFP (1470 μg per 109 
cells) (Fig. 7A). With this abundant starting material, and taking advantage of the 
engineered His10-tag, NiNTA affinity chromatography was employed to isolate 42 μg 
SUMO*-CFTRCFTR-EGFP (280 μg per 109 cells) with an overall recovery of 18% (Fig. 
7A). Coomassie blue staining of the same gel indicated that ~80% pure CFTR was achieved 
in a single chromatography step (Fig. 7B).
These same procedures were used to quantify SUMO*-CFTRFLAG-EGFP recoveries in 
replicate purification trials. We found a mean value of 1365 μg of SUMO*-CFTRFLAG-
EGFP per 109 cells in microsomal preparations from multiple batches of D165 cultures 
(Table 2). Of this, DDM solubilization and NiNTA affinity chromatography yielded 905 μg 
and 178 μg, respectively, per 109 cells (Table 2), representing average overall CFTR 
recoveries of 66% and 13%, respectively. Purity of ~80% was consistently observed (data 
not shown).
Potential aggregation of the purified SUMO*-CFTRFLAG-EGFP was assessed by FSEC. 
The SUMO*-CFTRFLAG-EGFP protein was eluted as a single, nearly symmetric peak 
without evidence of aggregated protein at the void volume (Fig. 8). The observed position of 
the peak would be consistent with either monomer or dimer. In a recent study, SUMO*-
CFTRFLAG-EGFP purified using similar procedures was active and appeared monomeric by 
cryo-electron microscopy (59). These results indicated that functional SUMO*-CFTRFLAG-
EGFP can be readily isolated from D165 cells in relative abundance using a mild detergent 
and without overt aggregation, suggesting the HEK293 mammalian cell culture system 
described in this study can provide a rich source of quality human CFTR protein for future 
biophysical investigation.
DISCUSSION
The challenge of obtaining human CFTR in sufficient quantities for biophysical studies is 
multifactorial, and persists as a fundamental obstacle to structure-based CF drug discovery. 
Mammalian cell expression systems offer the advantage of a physiologically relevant 
context for CFTR biogenesis so as to preserve native protein folding and post-translational 
modification (29). CFTR expressed constitutively in BHK cells retains chloride channel 
function (57), however, the cells produce only modest amounts of CFTR. In this study, we 
approached surmounting this obstacle by describing a linearly integrated strategy for 
modification of the protein and for evaluating its function and biogenesis in mammalian 
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cells, as well as enabling production and isolation of mature, biologically active human 
CFTR in preparative amounts.
The TRE-SUMO*-CFTRFLAG-EGFP-IRES-Puro expression strategy (Fig. 1A) comprises 
several important features that facilitate consistent production of high-quality recombinant 
human CFTR protein in mammalian cells. Expression of CFTR is tightly regulated using the 
Tet-On system (60). The HEK293.M2 (D017) cells used in this study express an enhanced 
rtTA that is stable in eukaryotic cells, exerts minimal basal expression from the TRE 
promoter, and is capable of inducing high-level transactivation of gene expression upon dox 
binding (61). We have found the inducible expression approach circumvents transcriptional 
silencing of CFTR observed in HEK293 cell cultures when expression was driven 
constitutively by the CMV promoter (unpublished results). With dox-controlled expression, 
CFTR-transduced HEK293 cells grow more rapidly and reach higher densities prior to 
induction compared to constitutively expressing HEK293 cells. The inducible expression 
strategy also facilitates the generation and procurement of characterized master-stock 
recombinant cell lines with stable genetic and biological properties. Thus, the strategy of 
controlled CFTR expression is vital for optimal maintenance and expansion of “quiescent” 
cells, as well as for maximizing CFTR production on a per-cell basis in response to dox. 
Indeed, in the case of SUMO*-CFTRFLAG-EGFP, mass-spectrometric analysis indicated 
CFTR expression levels in the mg per 109 cell range, approximately 1/10th of which was 
cell-surface localized even when overexpressed to these high levels. This expression system 
will, therefore, enable large-scale suspension cell cultures to be grown and induced under 
carefully optimized and standardized conditions to produce sufficient quantities of CFTR for 
biophysical studies.
Recording single-channel activity provides an informative measure of CFTR function, and is 
traditionally used to evaluate function of recombinant CFTR proteins expressed in various 
cell lines (56, 57). In this study, we identified combinations of heterologous tags/domains 
that add utility without seriously altering CFTR gating parameters or single-channel 
conductance (Fig. 4). The C-terminal EGFP and N-terminal SUMO* fusions were both 
functionally silent, while the extracellular loop FLAG insertion caused a slight decrease in 
single channel conductance, whether alone or in the CFTR construct containing all three 
tags, SUMO*-CFTRFLAG-EGFP. Nevertheless, the differences in the gating kinetics and 
single-channel conductance found between the unmodified and tagged CFTR variants were 
not dramatic, suggesting they have the same folded state.
Recombinant SUMO fusion proteins exhibit enhanced expression, decreased susceptibility 
to proteolytic degradation, and improved folding in E. coli and yeast (36, 37). For CFTR 
fusion, we utilized the SUMO* variant containing R64T and R71E mutations to prevent its 
cleavage by eukaryotic proteases (39). Analysis of the N-terminus of the fusion proteins by 
immunoblotting with anti-RGSHis4 mAb suggested that SUMO*-CFTR fusions were intact 
in HEK cells (Fig. 2). The presence of this domain proved advantageous for CFTR 
biogenesis in our system, since the comparative expression analysis indicated a 1.5- to 2-
fold increase in surface levels of SUMO*-CFTRFLAG-EGFP compared to CFTRFLAG-EGFP 
(Fig. 3B). If necessary for downstream applications, the SUMO* tag is removable with the 
highly specific SUMO* protease (36).
Hildebrandt et al. Page 11













Cell-surface localization of CFTR is important due to multiple quality control checkpoints 
preclude improperly folded CFTR from reaching this compartment (6). However, since 
extracellular loops of CFTR are relatively small and poorly exposed, high-avidity antibody 
probes to extracellular regions of the protein are not available for use in cell-surface 
compartmentalization analyses (33). Positioning a FLAG epitope tag in the fourth 
extracellular loop of CFTR enabled sensitive and specific analysis of CFTR cell-surface 
compartmentalization and augmented the derivation of high-producer cell lines. Insertion of 
FLAG at this site disrupts one of two N-glycosylation sites located in this loop, and band 
patterns in the immunoblot analysis (Fig. 2) were consistent with hemiglycosylation of 
FLAG-tagged CFTR variants. Previous studies indicated that this tag placement did not 
compromise plasma membrane compartmentalization of CFTR or channel function (33, 34). 
We confirmed that FLAG-tagged variants, including those with a SUMO* N-terminal 
fusion, traffic successfully to the cell-surface and channel function was essentially intact 
with only a small decrease in conductance. Cell-surface FLAG/CFTR was quantifiable by 
flow cytometry, and this signal correlated strongly with cell-surface CFTR measurements 
made by mass spectrometric analysis of surface-biotinylated CFTR (Fig. 6C). We also used 
FACS to specifically isolate the highest surface FLAG/CFTR-expressing cells from the 
transduced population. We found this to be a specific and efficient means to derive clonal 
cultures (such as D165) with favorable expression characteristics from among a diverse 
population, and we have recently extended the approach to facilitate studies of cell lines 
expressing CFTR orthologs (unpublished).
The C-terminal fusion of EGFP is especially useful for both real-time monitoring of CFTR 
expression in live cultures and rapid evaluation of subcellular distribution by fluorescence 
microscopy. Flow cytometry of GFP fluorescence may be used for quantitation and 
facilitates cell sorting to isolate highly expressing subpopulations and derivation of clonal 
cell lines. Downstream, EGFP proved invaluable for CFTR quantitation both in crude cell 
lysates and successive protein purification steps. Using quantitative in-gel fluorescence 
methods, our results show that microsomal membranes contained 1.4 mg of SUMO*-
CFTRFLAG-EGFP per 109 D165 suspension cells (Table 2). From this starting material, 
using standard methods of detergent solubilization and affinity purification, we recovered 
180 μg CFTR per 109 cells at ~80% purity. Moreover, FSEC demonstrated that purified 
SUMO*-CFTRFLAG-EGFP was monodisperse (Fig. 8). These and recently published results 
(59) indicate that SUMO*-CFTRFLAG-EGFP can be readily isolated and purified in relative 
abundance, suggesting the mammalian cell culture system described here can provide a rich 
source of quality CFTR for biophysical investigations.
Our findings describe the development and validation of a robust mammalian cell 
expression system that facilitates reproducible and standardized large scale production of 
exogenous, biologically active cell-surface human CFTR protein. Importantly, the molecular 
expression strategy we used is vertically integrated to enhance efficiency and augment 
identification and derivation of stable high-producer cells, improve reproducibility and 
standardization of lot production, and facilitate analytical assessment at multiple steps from 
surface expression and cell isolation to monitoring of SUMO*-CFTRFLAG-EGFP 
solubilization and purification. With this expression platform in place, we anticipate that 
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future studies with stabilizing mutations and CFTR orthologs will inform research efforts to 
stabilize the CFTR protein, as a prerequisite for the solution of its structure.
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Figure 1. Vectors used to generate stably transduced HEK293 cell lines expressing recombinant 
CFTR
Illustration of expression cassettes comprising wild-type CFTR (CFTR), CFTR containing 
the FLAG epitope tag in the fourth extracellular loop (CFTRFLAG), CFTRFLAG fused in-
frame with EGFP (CFTRFLAG-EGFP), RGSHis10-SUMO*-tagged CFTRFLAG-EGFP 
(SUMO*-CFTRFLAG-EGFP), and RGSHis10-SUMO*-tagged CFTR-EGFP (SUMO*-
CFTR-EGFP). EGFP encodes the A206K mutation to minimize self-dimerization (25). Each 
of the illustrated expression cassettes represents a genetic sequence inserted into a lentiviral 
vector for delivery and stable integration into HEK293.M2 cells. These vectors contain a 
TRE promoter followed by CFTR sequence, IRES, and either the puromycin resistance gene 
or a puromycin-T2A-EGFP open reading frame. T2A, a member of the 2A peptide family, 
comprises a 19 amino acid sequence that causes a co-translational separation in the synthesis 
of the puromycin and EGFP polypeptides (30-32).
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Figure 2. Western blot analysis of recombinant CFTR expression
Puromycin resistant and dox-induced monolayer cultures of transduced HEK293.M2 cells 
were lysed in Laemmli sample buffer, adjusted to 5 × 104 cell equivalents per 10 μl, and 
analyzed by immunoblotting with either anti-CFTR mAb R1104 or anti-RGSHis4 mAb. 
Arrowheads mark complex-glycosylated (band C ▶) and core-glycosylated (band B ) forms 
of CFTR. In FLAG-tagged proteins, one of the two sites for N-glycosylation was disrupted. 
By densitometry, about 68% and 33 ± 10% (n=10) of the SUMO*-CFTRFLAG-EGFP 
protein was found in bands C and B, respectively. Molecular-weight markers are shown on 
the left in kDa. Calculated masses of the SUMO*-CFTRFLAG-EGFP, CFTRFLAG-EGFP and 
CFTR polypeptides are 212, 197, and 168 kDa, respectively. The 65 kDa band recognized 
by CFTR-specific antibody R1104 was not observed with RGS-His antibody or by in-gel 
EGFP fluorescence, and could represent a CFTR fragment or nonspecific cross-reactive 
protein. The results shown are representative of two independent analyses.
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Figure 3. Analysis of recombinant CFTR expression by flow cytometry
(A) Cells were treated with 1 μg/ml of dox for 24 hrs and then live-stained for surface 
FLAG/CFTR expression using SureLight anti-FLAG mAb. The distribution of fluorescence 
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intensity of EGFP and FLAG staining is shown for each of the cell populations analyzed: 
HEK293.M2 (control), SUMO*-CFTRFLAG-EGFP, CFTRFLAG-EGFP, CFTRFLAG and 
D165. D165 is a clonal derivative of the D158 cell line expressing SUMO*-CFTRFLAG-
EGFP. HEK293.M2 cells that do not express CFTR were included as a negative control. (B) 
The indicated cultures were immunostained for cell-surface FLAG epitope 24, 48 or 72 hrs 
after dox induction and analyzed by flow cytometry as in (A). LinearFlow® Fluorescently 
labeled polystyrene beads (Molecular Probes) were analyzed in parallel to control for 
possible inter-assay variation of the flow cytometer. MFI values for each cell population 
were calculated from two independent experiments.
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Figure 4. CFTR channel analysis
Single-channel currents detected in microsomal membranes isolated from BHK cells 
constitutively expressing wild-type CFTR (top panel) and HEK293.M2 cells expressing 
either wild-type (second panel), or recombinant forms of CFTR (lower three panels), are 
shown in the middle section of each panel. All-points histograms used to define single-
channel current as the distance between peaks on the graph and calculate single-channel 
conductance (γ) are shown on the left of each panel. Values for probability of the open state 
(Po) were calculated as the ratio of the area under the peak for the open state to the total area 
under both peaks on the all-points histogram. Dwell-time histograms for the mean open (τo) 
and closed (τc) times are shown on the right of each panel. The validity of the reduced two 
Hildebrandt et al. Page 21













states kinetic model C ⇌ O is evident from the single exponential fit shown in each dwell 
time histogram.
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Figure 5. Immunofluorescence microscopy analysis of SUMO*-CFTRFLAG-EGFP cell-surface 
expression
Hildebrandt et al. Page 23













(A) SUMO*-CFTRFLAG-EGFP cells were treated with dox (1 μg/ml) for 24 hrs, and then 
live-stained for extracellular FLAG. FLAG immunostaining was analyzed by confocal laser-
scanning microscopy. A z-stack of 0.45 micron optical sections was captured, and the 
composite image is illustrated in red with DAPI-stained cell (blue) nuclei. (B-D) For 
analysis of protein colocalization, expression of SUMO*-CFTRFLAG-EGFP (B, D) and 
SUMO*-CFTR-EGFP (C) was dox-induced (1 μg/ml) for 24 hrs and examined by wide-
field fluorescence microscopy using a Nikon Eclipse TE2000-s inverted microscope. Either 
live/intact (B and C) or fixed and permeabilized (D) cells were immunostained to detect the 
FLAG epitope. Images of EGFP (green) and FLAG-stain fluorescence (red) are depicted. A 
composite of the two fluorescent images (merged) is shown in column 3. DAPI-stained cell 
nuclei are shown in blue.
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Figure 6. Quantitative mass spectrometry analysis of cell-surface SUMO*-CFTRFLAG-EGFP
Replicate SUMO*-CFTRFLAG-EGFP cultures (D165 cells) comprising approximately 107 
cells were treated for 24 hrs with dox concentrations ranging from 0.0007 to 0.5 μg/ml. (A) 
Relative surface expression levels of SUMO*-CFTRFLAG-EGFP were determined using 
flow cytometry to analyze fluorescence from intact/live cells immunostained with SureLight 
anti-FLAG M2 mAb. The mean fluorescence intensities (MFI) of stained cell populations 
were plotted for each dox-treatment concentration. (B) In parallel replicate cultures, mass 
measurements of surface biotinylated (SB) SUMO*-CFTRFLAG-EGFP were determined by 
quantitative mass spectrometry. The background value, determined by analyzing HEK293 
cells, is demarked on the plot by the horizontal dotted line. Results are expressed as μg of 
SB CFTR per 109 cells. (C) Correlation between mass spectrometry (SB CFTR, μg/109 
cells) and flow cytometry (MFI) measurements of surface CFTR. The linear regression 
coefficient, r2, = 0.961.
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Figure 7. Facile detergent solubilization and affinity purification of SUMO*-CFTRFLAG-EGFP
Microsomes isolated from D165 suspension-culture cells were solubilized with DDM and 
the extract was bound to NiNTA. After washing, SUMO*-CFTRFLAG-EGFP was eluted 
with imidazole. (A) Samples of microsomes (8 μg), DDM extract (8 μg), and NiNTA 
purified (~80%) CFTR (32 μl, 4 μl) were resolved on an 8% SDS-PAGE gel; a fluorescent 
image of the gel is shown. Known amounts of SUMO-EGFP fusion protein were loaded on 
the gel to generate a standard curve (inset), allowing quantitation of fluorescent CFTR 
bands. (B) A section of the same gel shown in (A) stained with Coomassie blue. Masses of 
molecular weight markers, in kDa, are shown on the right.
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Figure 8. Monodispersity of affinity-purified SUMO*-CFTRFLAG-EGFP
Protein eluted from NiNTA (25 μl containing 1.7 μg CFTR) was analyzed by FSEC on a 2.4 
ml column. The peak of SUMO*-CFTRFLAG-EGFP (212 kDa) was eluted at 1.62 ml, near 
that of the monomeric P-glycoprotein-EGFP fusion protein (172 kDa), at 1.73 ml that is 
routinely used as a standard with FSEC assays. The arrow indicates the column void volume 
at 1.05 ml.
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Table 1
Mass spectrometry transitions
Peptide Sequence Type of transition Transition
Native CFTR01 NSILTETLHR [M+2H]2+→y7 592.3→869.5
SILAC CFTR01 NSI-[1,2-13C-L]-TET-[1,2-13C-L]-HR [M+2H]2+→y7 594.8→873.5
Native CFTR02 LSLVDSEQGEAILPR [M+2H]2+→y12 862.5→1311.7
SILAC CFTR02 [1,2-13C-L]S[1,2-13C-L]VDSEQGEAI[1,2-13C-L]PR [M+2H]2+→y12 865.5→1313.7
Native CFTR04 NSILNPINSIR [M+2H]2+→y8 620.8→926.5
SILAC CFTR04 NSI[1,2-13C-L]NPINSIR [M+2H]2+→y8 621.9→928.5
SILAC: stable isotope labeling in cell culture
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Table 2
Quantitative analyses of SUMO*-CFTRFLAG-EGFP expression
μg CFTR per 109 cells Quantitation method
Total cellular CFTR 3581 ± 674 (n=3) mass spectrometry
CFTR at the cell-surface 363 ± 31 (n=3) mass spectrometry
Microsomes 1365 ± 485 (n=9) EGFP fluorescence
DDM extract
1 905 ± 220 (n=8) EGFP fluorescence
Affinity purified CFTR
1 178 ± 56 (n=10) EGFP fluorescence
1
CFTR was extracted and purified from microsomal fractions as in Figure 7. Values are means standard deviation for n replicate experiments.
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